Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Kiora Pharmaceuticals Inc KPRX

Kiora Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment of orphan retinal diseases. Its pipeline consists of three product candidates, including KIO-301, KIO-104, KIO-101 and KIO-201. Its lead product, KIO-301, is a vision-restoring small molecule that is designed to restore vision in patients... see more

NDAQ:KPRX - Post Discussion

Kiora Pharmaceuticals Inc > What's Going On With Kiora Pharmaceuticals Stock? | Benzinga
View:
Post by whytestocks on Feb 01, 2024 12:15pm

What's Going On With Kiora Pharmaceuticals Stock? | Benzinga

Just In: $KPRX What's Going On With Kiora Pharmaceuticals Stock? | BenzingaKiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares are trading higher Thursday after the company announced a private placement of up to $45 million a...KPRX - What's Going On With Kiora Pharmaceuticals Stock? | Benzinga
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities